Сексуальные расстройства у пациентов с заболеваниями шизофренического спектра, получающих терапию атипичными антипсихотиками
Рекомендуемое оформление библиографической ссылки:
Соболев Н.А., Ягубов М.И. Сексуальные расстройства у пациентов с заболеваниями шизофренического спектра, получающих терапию атипичными антипсихотиками // Российский психиатрический журнал. 2017. №1. С. 37-48.
В статье представлен обзор современной литературы по проблеме сексуальной дисфункции у больных с расстройствами шизофренического спектра. Анализ имеющихся данных позволяет сделать вывод о том, что расстройства сексуальной функции шире распространены среди данной группы больных, чем в популяции в целом. Факторами формирования сексуальной дисфункции могут служить психофармакотерапия, продуктивная и негативная симптоматика в рамках основного заболевания, социальная дезадаптация, стигматизация. Обсуждаются основные направления решения данной медико-социальной проблемы. Результаты проведенного исследования могут быть использованы с целью дальнейшего планирования научной-исследовательских мероприятий.
1. Lubov E.B. Socio-economic burden of schizophrenia. Sotsial'naya i klinicheskaya psikhiatriya. [Social and clinical psychiatry]. 2012; Vol 22 (2): 100-8. (in Russian) 2. Kaplan H.I., Sadock, B.J. Clinical psychiatry from synopsis of psychiatry. Moscow, 1998: 672 р. (in Russian) 3. Mosolov S.N. Biological methods of mental disorders therapy (evidence-based medicine to clinical practice). Moscow, 2012: 1080 p. (in Russian). 4. Gorobets L.N. Neuroendocrine dysfunctions and neuroleptic treatment. Medpraktika [Medical practice]. 2007; 311 p. (in Russian). 5. Baggaley M. Sexual dysfunction in schizophrenia: focus on recent evidence. Human psychopharmacology: clinical and experimental. 2008; Vol. 23(3): 201-9. 6. Zemishlany Z., Weizman A. The Impact of Mental Illness on Sexual Dysfunction. Adv Psychosom Med. 2008; Vol. 29: 89-106. 7. Bhui K., Puffet A., Herriot P. A survey of sexual problems amongst psychiatric inpatients. Soc. Psychiatry Psychiatr. Epidemiol. 1995; Vol. 30, No. 2:73-7. 8. Teusch L., Scherbaum N., Böhme H. et al. Different patterns of sexual dysfunctions associated with psychiatric disorders and psychopharmacological treatment. Results of an investigation by semistructured interview of schizophrenic and neurotic patients and methadone-substituted opiate addicts. Pharmacopsychiatry. 1995; Vol. 28(3):84-92. 9. Shtark L.N., Yagoubov M.I. Sexual dysfunctions developing in the course of treatment with antipsychotics in patients with schizophrenia. Obozrenie psihiatrii i meditsinskoy psihologii imeni V.M. Behtereva [V.M. Bekhterev review of psychiatry and medical psychology]. 2010; Vol. 2: 8-13. (in Russian) 10. Kotin J., Wilbert D. E., Verburg D. et al. Thioridazine and sexual dysfunction. Am J Psychiatry. 1976; Vol.133(1):82-5. 11. Fujii A., Yasui-Furukori N., Sugawara N. Sexual dysfunction in Japanese patients with schizophrenia treated with antipsychotics. Prog. Neuropsychopharmacol Biol. Psychiatry. 2010; Vol. 34(2):288-93. 12. Dossenbach M., Dyachkova Y., Pirildar S. et al. Effects of atypical and typical antipsychotic treatments on sexual function in patients with schizophrenia: 12-month results from the Intercontinental Schizophrenia Outpatient Health Outcomes (IC-SOHO) study. Eur. Psychiatry. 2006; Vol. 21(4):251-8. 13. Dossenbach M., Hodge A., Anders M. et al. Prevalence of sexual dysfunction in patients with schizophrenia: international variation and underestimation. Int. J. Neuropsychopharmacol. 2005; Vol. 8(2):195-201. 14. Knegtering H., van den Bosch R., Castelein S. et al. Are sexual side effects of prolactin- raising antipsychotics reducible to serum prolactin Psychoneuroendocrinology. 2008; Vol. 33, No. 6:711-7. 15. de Boer M. K., Castelein S., Wiersma D. et al. The facts about sexual (dys) function in schizophrenia: an overview of clinically relevant findings. Schizophr. Bull. 2015; Vol. 41(3):674-86. 16. Meston C. M., Frohlich P.F. The neurobiology of sexual function. Arch. Gen. Psychiatry. 2000 ; Vol. 57, No. 11:1012-30. 17. Serretti A., Chiesa A. A meta-analysis of sexual dysfunction in psychiatric patients taking antipsychotics. Int. Clin. Psychopharmacol. 2011 ; Vol. 26(3):130-40. 18. de Boer M.K., Wiersma D., Bous J. et al. A randomized open-label comparison of the impact of aripiprazole versus risperidone on sexual functioning (RAS study). J. Clin. Psychopharmacol. 2011 ; Vol. 31(4):523-5. 19. Aizenberg D. Zemishlany Z. Dorfman-Etrog P. Sexual dysfunction in male schizophrenic patients. J. Clin. Psychiatry. 1995; Vol. 56(4):137-41. 20. Knegtering H., van der Moolen A.E., Castelein S. et al. What are the effects of antipsychotics on sexual dysfunctions and endocrine functioning? Psychoneuroendocrinology. 2003 ; Vol. 28(Suppl 2):109–23. 21. Compton M.T., Miller A.H. Priapism associated with conventional and atypical antipsychotic medications: a review. J. Clin. Psychiatry. 2001;Vol. 62(5):362-6. 22. Sood S., James W., Bailon M.J. Priapism associated with atypical antipsychotic medications: a review. Int. Clin. Psychopharmacol. 2008; Vol. 23(1):9-17. 23. Bucur M., Mahmood T. Olanzapine-induced clitoral priapism. J Clin Psychopharmacol. 2004 ;Vol. 24, No.5:572-3. 24. Shader R.I., Elkins R. The effects of antianxiety and antipsychotic drugs and sexual behavior. Mod. Probl. Pharmacopsychiatry. 1980;Vol.15:91-110. 25. Girgis S.M., Etriby A., el-Hefnawy H. et al. Aspermia: a survey of 49 cases. Fertil Steril. 1968;Vol.19(4):580-8. 26. Patel A.G., Mukherji K., Lee A. Priapism associated with psychotropic drugs. Br. J. Hosp. Med. 1996; Vol. 55(6):315-9. 27. Gitlin M.J. Psychotropic medications and their effects on sexual function: diagnosis, biology, and treatment approaches. J. Clin. Psychiatry. 1994;Vol. 55(9):406-13. 28. Ichikawa J., Ishii H., Bonaccorso S. 5-HT(2A) and D(2) receptor blockade increases cortical DA release via 5-HT(1A) receptor activation: a possible mechanism of atypical antipsychotic-inducedcortical dopamine release. J. Neurochem. 2001;Vol. 76(5):1521-31. 29. Keitner G.I., Selub S. Spontaneous ejaculations and neuroleptics. J. Clin. Psychopharmacol. 1983 ;Vol. 3(1):34-6. 30. Berger S.H. Trifluoperazine and haloperidol: sources of ejaculatory pain? Am. J. Psychiatry. 1979;Vol.136(3):350. 31. Ghadirian A.M., Chouinard G., Annable L. Sexual dysfunction and plasma prolactin levels in neuroleptic-treated schizophrenic outpatients. J. Nerv. Ment. Dis. 1982;Vol.170(8):463-7. 32. Aizenberg D., Modai I., Landa A. et al. Comparison of sexual dysfunction in male schizophrenic patients maintained on treatment with classical antipsychotics versus clozapine. J Clin. Psychiatry. 2001; Vol. 62(7):541-4. 33. Ouwehand A.J., Mollema-Schelwald B.M., Knegtering H. The relationship between antipsychotic-induced hyperprolactinemia and menstrual disorders in women with schizophrenia; a systematic review. Tijdschr. Psychiatr. 2012; Vol. 54(10):861-8. 34. Jacobs P., Bobek S.C. Sexual needs of the schizophrenic client. Perspect. Psychiatr. Care. 1991;Vol. 27(1):15-20. 35. Norman J.P. Evidence and clinical significance of homosexuality in 100 unanalyzed cases of dementia praecox. J. Nerv. Ment. Dis. 1948; Vol. 107(5):484-9. 36. Arieti S. New views on the psychodynamics of schizophrenia. Am. J. Psychiatry. 1967; Vol. 124 , No. 4:453-8. 37. Shtark L.N., Yagoubov M.I., Shmukler A.B. et al. Sexual dysfunctions developing in the course of treatment with antipsychotics in patients with schizophrenia at early stages of disease. Sotsial'naya i klinicheskaya psikhiatriya. [Social and clinical psychiatry]. 2011; Vol. 21(4); 77-84. (in Russian) 38. Raboch J. The sexual development and life of female schizophrenic patients. Arch. Sex. Behav. 1984 ;Vol. 13(4):341-9. 39. Barnes T.R., Harvey C.A. Psychiatric drugs and sexuality. Sexual pharmacology. 1993;176-96. 40. Giuliano F., Allard J. Dopamine and sexual function. Int. J. Impot. Res. 2001; Vol.3:18-28. 41. Rao M.L., Gross G., Halaris A. et al. Hyperdopaminergia in schizophreniform psychosis: a chronobiological study. Psychiatry Res. 1993;Vol. 47(2):187-203. 42. Meltzer H.Y., Sachar E.J., Frantz A.G. Serum prolactin levels in unmedicated schizophrenic patients. Arch. Gen. Psychiatry. 1974. Vol.31(4):564-9. 43. Keks N.A., Copolov D.L., Singh B.S. Abnormal prolactin response to haloperidol challenge in men with schizophrenia. Am. J. Psychiatry. 1987; Vol. 144(10):1335-7. 44. Kuruvilla A., Peedicayil J., Srikrishna G., et al. A study of serum prolactin levels in schizophrenia: comparison of males and females. Clin. Exp. Pharmacol. Physiol. 1992; Vol.19(9):603-6. 45. Beck-Friis J., Ljunggren J.G., Thoren M. et al. Melatonin, cortisol and ACTH in patients with major depressive disorder and healthy humans with special reference to the outcome of the dexamethasone suppression test. Psychoneuroendocrinology. 1985;Vol. 10(2):173-86. 46. Goetze U., Tolle R. Circadian rhythm of free urinary cortisol, temperature and heart rate in endogenous depressives andunder antidepressant therapy. Neuropsychobiology. 1987; Vol.18(4):175-84. 47. Howes O.D., Wheeler M.J., Pilowsky L.S. et al. Sexual function and gonadal hormones in patients taking antipsychotic treatment for schizophrenia or schizoaffective disorder. J. Clin. Psychiatry. 2007; Vol. 68(3):361-7. 48. Mir A., Shivakumar K., Williamson R.J. Change in sexual dysfunction with aripiprazole: a switching or add-on study. J Psychopharmacol. 2008; Vol. 22(3):244-53. 49. Chen J.X., Su Y.A., Wang S.L. et al. Aripiprazole treatment of risperidone-induced hyperprolactinemia. J. Clin. Psychiatry. 2009; Vol. 70(7):1058-9. 50. Leysen J.E., Gommeren W. The dissociation rate of unlabelled receptor, application of an original filter method. J. Recept. Res. 1984; Vol. 4(7):817-45. 51. Correll C.U. From receptor pharmacology to improved outcomes: individualising the selection, dosing, and switching of antipsychotics. Eur. Psychiatry. 2010; Vol. 25(2):12-21. 52. Richtand N.M., Welge J.A., Logue A.D. Role of serotonin and dopamine receptor binding in antipsychotic efficacy. Prog. Brain Res. 2008; Vol.172:155-75. 53. Thompson J.W. Jr., Ware M.R., Blashfield R.K. Psychotropic medication and priapism: a comprehensive review. J. Clin. Psychiatry. 1990; Vol. 51(10):430-3. 54. Sanbe A., Tanaka Y., Fujiwara Y. et al. Alpha1-adrenoceptors are required for normal male sexual function. Br. J. Pharmacol. 2007; Vol.152(3):332-40. 55. Smith E.R., Lee R.L., Schnur S.L. et al. Alpha 2-adrenoceptor antagonists and male sexual behavior: II. Erectile and ejaculatory reflexes. Physiol. Behav. 1987; Vol.41(1):15-9. 56. Tallentire D., McRae G., Spedding M. et al. Modulation of sexual behaviour in the rat by a potent and selective alpha 2-adrenoceptor antagonist, delequamine (RS-15385-197). Br. J. Pharmacol. 1996; Vol. 118(1):63-72. 57. Floody O.R. Cholinergic control of male mating behavior in hamsters: effects of systemic agonist or antagonist treatment. Pharmacol. Biochem. Behav. 2011; Vol. 100(2):289-98. 58. Canevelli M., Talarico G., Tosto G. et al. Rivastigmine in the treatment of hypersexuality in Alzheimer disease. Alzheimer. Dis. Assoc. Disord. 2013; Vol. 27(3):287-8. 59. White J.M., Rumbold G.R. Behavioural effects of histamine and its antagonists: a review. Psychopharmacology (Berl). 1988; Vol. 95(1):1-14. 60. Uckert S., Wilken M., Stief C. et al. Is there a significance of histamine in the control ofthe human male sexual response? Andrologia. 2012; Vol. 44(Suppl 1):538-42. 61. Rettenbacher M.A., Hofer A., Ebenbichler C. et al. Prolactin levels and sexual adverse effects in patients with schizophrenia during antipsychotic treatment. J. Clin. Psychopharmacol. 2010; Vol.30(6):711-5. 62. Melkersson K. Differences in prolactin elevation and related symptoms of atypical antipsychotics in schizophrenic patients. J. Clin. Psychiatry. 2005;Vol.66(6):761-7. 63. Macdonald S., Halliday J., MacEwan T. et al. Nithsdale Schizophrenia Surveys 24: sexual dysfunction Case-control study. Br. J. Psychiatry. 2003; Vol.182:50-6. 64. Malik P., Kemmler G., Hummer M. et al. Sexual dysfunction in firstepisode schizophrenia patients: Results from European First Episode Schizophrenia Trial. J. Clin. Psychopharmacol. 2011; Vol. 31(3):274-80. 65. Gopalakrishnan R., Jacob K.S., Kuruvilla A. et al. Sildenafil in the treatment of antipsychotic-induced erectile dysfunction: a randomized, double-blind, placebo controlled, flexible-dose, two-way crossover trial. Am. J. Psychiatry. 2006; Vol.163(3):494-9. 66. Costa A.M., Lima M.S., Mari Jde J. A systematic review on clinical management of antipsychotic-induced sexual dysfunction in schizophrenia. Sao Paulo Med. J. 2006; Vol.124(5):291-7. 67. Kodesh A., Weizman A., Aizenberg D. Selegiline in the treatment of sexual dysfunction in schizophrenic patients maintained on neuroleptics: a pilot study. Clin. Neuropharmacol. 2003; Vol.26(4):193-5. 68. Kelly D.L., Conley R. R. Sexuality and schizophrenia: a review. Schizophr. Bull. 2004;Vol.30(4):767-79. 69. Cutler A.J. Sexual dysfunction and antipsychotic treatment. Psycho neuroendo crinology. Psycho neuro endo crinology. 2003; Vol.28(1):69-82. 70. Olfson M., Uttaro T., Carson W.H. Male sexual dysfunction and quality of life in schizophrenia. J Clin Psychiatry. 2005;Vol.66(3):331-8. 71. Park Y., Kim Y., Lee J. Antipsychotic-Induced Sexual Dysfunction and Its Management.World J. Mens Health. 2012;Vol.30(3):153-9. 72. Kinon B.J., Ahl J., Liu-Seifert H. et al. Improvement in hyperprolactinemia and reproductive comorbidities in patients with schizophrenia switched from conventional antipsychotics or risperidone to olanzapine. Psychoneuroendocrinology. 2006;Vol.31(5):577-88. 73. Ahl J., Kinon B.J., Liu-Seifert H. Sexual dysfunction associated with neuroleptic-induced hyperprolactinemia improves with reduction in prolactin levels. Ann. N. Y. Acad. Sci. 2004;Vol.1032:289-90. 74. Kim K.S., Pae C.U., Chae J.H. et al. Effects of olanzapine on prolactin levels of female patients with schizophrenia treated with risperidone. J. Clin. Psychiatry. 2002;Vol.63(5):408-13. 75. Nunes L.V., Moreira H.C., Razzouk D. Strategies for the treatment of antipsychotic-induced sexual dysfunction and/or hyperprolactinemia among patients of the schizophrenia spectrum: a review. J. Sex Marital Ther. 2012;Vol.38(3):281-301. 76. Nakonezny P.A., Byerly M.J., Rush A.J. The relationship between serum prolactin level and sexual functioning among male outpatients with schizophrenia or schizoaffective disorder: A randomized doubleblind trial of risperidone vs. quetiapine. J. Sex Marital Ther. 2007; Vol.33(3):203-16. 77. Byerly M.J., Nakonezny P.A., Rush A.J. Sexual functioning associated with quetiapine switch vs. risperidone continuation in outpatients with schizophrenia or schizoaffective disorder: A randomized double-blind pilot trial. Psychiatry Res. 2008; Vol.159(1-2):115-20. 78. Ivanov M.V., Chomskiy A.N., Kazantseva K.V. Psychoendocrinological aspects of schizophrenic patients’ therapy with quetiapine. Psihiatriya i psihofarmakoterapiya [Psychiatry and psychopharmacology]. 2009; Vol.11(4); 42-7. (in Russian) 79. Hanssens L., L'Italien G., Loze J.Y. et al. The effect of antipsychotic medication on sexual function and serum prolactin levels in communitytreated schizophrenic patients: results from the Schizophrenia Trial of Aripiprazole (STAR) study BMC Psychiatry. 2008; Vol.8:95. 80. Shim J.C., Shin J.G., Kelly D.L. et al. adjunctive treatment with a dopamine partial agonist, aripiprazole, for antipsychotic-induced hyperprolactinemia: a placebo-controlled trial. Am. J. Psychiatry. 2007; Vol.164(9): 1404-10. 81. Nunes L.V., Lacaz F.S., Bressan R.A. et al. Adjunctive treatment with lodenafil carbonate for erectile dysfunction in outpatients with schizophrenia and spectrum: a randomized, double-blind, crossover, placebo-controlled trial. J. Sex Med. 2013; Vol.10(4):1136-45. 82. Haddad P.M., Wieck A. Antipsychotic-induced hyperprolactinemia: mechanisms, clinical features and management. Drugs. 2004; Vol.64(20):2291-314. 83. Shtark L.N., Vvedensky G.E. Specifics of rehabilitationpsychotherapeutic programs for sex offenders. Rossiyskiy psikhiatricheskiy zhurnal. [Russian journal of psychiatry]. 2015. Vol.2:50-5. (in Russian)
DOI: http://dx.doi.org/10.24411/1560-957X-2017-1%25x
Метрики статей
Metrics powered by PLOS ALM